Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
World Journal of Surgical Oncology
Published in: World Journal of Surgical Oncology 1/2012

Open Access 01-12-2012 | Research

Relationships between serum HER2 ECD, TIMP-1 and clinical outcomes in Taiwanese breast cancer

Authors: Hsiu-Pei Tsai, Shin-Cheh Chen, Huei-Tzu Chien, Yi-Yin Jan, Tzu-Chieh Chao, Miin-Fu Chen, Ling-Ling Hsieh

Published in: World Journal of Surgical Oncology | Issue 1/2012

Login to get access

Abstract

Background

Serum levels of the extracellular domain of HER2/neu (HER2 ECD) have been demonstrated to be associated with clinical outcomes. A disintegrin and metalloproteinase-10, a sheddase of HER2/neu, can drive cancer progression and its activity is inhibited by tissue inhibitor of metalloproteinase-1 (TIMP-1). However, elevated TIMP-1 expression has been associated with a poor prognosis of breast cancer. Therefore, this study was performed to explore the relationships between serum HER2 ECD, TIMP-1 and clinical outcomes.

Methods

One hundred and eighty-five female breast cancer patients, who received curative mastectomy without neo-adjuvant chemotherapy at Chang-Gung Memorial Hospital, were recruited with informed consent for this study. Pre-operative serum levels of HER2 ECD and TIMP-1 were measured using an enzyme-linked immunosorbent assay.

Results

Twenty-three cases (12.4%) were classified HER2 ECD positive. HER2 ECD positivity was significantly associated with age, lymph node involvement, histological grade, estrogen receptor status, progesterone receptor status, tissue HER2/neu overexpression, and disease-free survival (DFS). In an age, stage, ER and HER2/neu status matched subgroup (N = 41), the serum level of TIMP-1 was significantly associated with HER2 ECD positivity and DFS.

Conclusions

A high serum TIMP-1 was significantly associated with HER2 ECD positivity and a poorer DFS among Taiwanese primary breast cancer patients with HER2 overexpression.
Appendix
Available only for authorised users
Literature
1.
Freudenberg JA, Wang Q, Katsumata M, Drebin J, Nagatomo I, Greene MI: The role of HER2 in early breast cancer metastasis and the origins of resistance to HER2-targeted therapies. Exp Mol Pathol. 2009, 87: 1-11. 10.1016/j.yexmp.2009.05.001.PubMedCentralCrossRefPubMed
2.
Roses RE, Paulson EC, Sharma A, Schueller JE, Nisenbaum H, Weinstein S, Fox KR, Zhang PJ, Czerniecki BJ: HER-2/neu overexpression as a predictor for the transition from in situ to invasive breast cancer. Cancer Epidemiol Biomarkers Prev. 2009, 18: 1386-1389. 10.1158/1055-9965.EPI-08-1101.PubMedCentralCrossRefPubMed
3.
Xu FJ, Stack S, Boyer C, O'Briant K, Whitaker R, Mills GB, Yu YH, Bast RC: Heregulin and agonistic anti-p185(c-erbB2) antibodies inhibit proliferation but increase invasiveness of breast cancer cells that overexpress p185(c-erbB2): increased invasiveness may contribute to poor prognosis. Clin Cancer Res. 1997, 3: 1629-1634.PubMed
4.
Tovey SM, Brown S, Doughty JC, Mallon EA, Cooke TG, Edwards J: Poor survival outcomes in HER2-positive breast cancer patients with low-grade, node-negative tumours. Br J Cancer. 2009, 100: 680-683. 10.1038/sj.bjc.6604940.PubMedCentralCrossRefPubMed
5.
De Placido S, Carlomagno C, De Laurentiis M, Bianco AR: c-erbB2 expression predicts tamoxifen efficacy in breast cancer patients. Breast Cancer Res Treat. 1998, 52: 55-64. 10.1023/A:1006159001039.CrossRefPubMed
6.
Henderson IC, Patek AJ: The relationship between prognostic and predictive factors in the management of breast cancer. Breast Cancer Res Treat. 1998, 52: 261-288. 10.1023/A:1006141703224.CrossRefPubMed
7.
Meng S, Tripathy D, Shete S, Ashfaq R, Haley B, Perkins S, Beitsch P, Khan A, Euhus D, Osborne C: HER-2 gene amplification can be acquired as breast cancer progresses. Proc Natl Acad Sci USA. 2004, 101: 9393-9398. 10.1073/pnas.0402993101.PubMedCentralCrossRefPubMed
8.
Tsutsui S, Ohno S, Murakami S, Kataoka A, Kinoshita J, Hachitanda Y: Comparison of the immunohistochemical expression of EGFR, c-erbB2 and p53 protein between primary and recurrent breast cancer. Breast Cancer. 2002, 9: 111-117. 10.1007/BF02967575.CrossRefPubMed
9.
Simon R, Nocito A, Hubscher T, Bucher C, Torhorst J, Schraml P, Bubendorf L, Mihatsch MM, Moch H, Wilber K: Patterns of her-2/neu amplification and overexpression in primary and metastatic breast cancer. J Natl Cancer Inst. 2001, 93: 1141-1146. 10.1093/jnci/93.15.1141.CrossRefPubMed
10.
Molina MA, Saez R, Ramsey EE, Garcia-Barchino MJ, Rojo F, Evans AJ, Albanell J, Keenan EJ, Lluch A, Garcia-Conde J: NH(2)-terminal truncated HER-2 protein but not full-length receptor is associated with nodal metastasis in human breast cancer. Clin Cancer Res. 2002, 8: 347-353.PubMed
11.
Lennon S, Barton C, Banken L, Gianni L, Marty M, Baselga J, Leyland-Jones B: Utility of serum HER2 extracellular domain assessment in clinical decision making: pooled analysis of four trials of trastuzumab in metastatic breast cancer. J Clin Oncol. 2009, 27: 1685-1693. 10.1200/JCO.2008.16.8351.CrossRefPubMed
12.
Leary AF, Hanna WM, van de Vijver MJ, Penault-Llorca F, Ruschoff J, Osamura RY, Bilous M, Dowsett M: Value and limitations of measuring HER-2 extracellular domain in the serum of breast cancer patients. J Clin Oncol. 2009, 27: 1694-1705. 10.1200/JCO.2008.17.3989.CrossRefPubMed
13.
Harris L, Fritsche H, Mennel R, Norton L, Ravdin P, Taube S, Somerfield MR, Hayes DF, Bast RC: American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol. 2007, 25: 5287-5312. 10.1200/JCO.2007.14.2364.CrossRefPubMed
14.
Page-McCaw A, Ewald AJ, Werb Z: Matrix metalloproteinases and the regulation of tissue remodelling. Nat Rev Mol Cell Biol. 2007, 8: 221-233. 10.1038/nrm2125.PubMedCentralCrossRefPubMed
15.
Talvensaari-Mattila A, Paakko P, Turpeenniemi-Hujanen T: Matrix metalloproteinase-2 (MMP-2) is associated with survival in breast carcinoma. Br J Cancer. 2003, 89: 1270-1275. 10.1038/sj.bjc.6601238.PubMedCentralCrossRefPubMed
16.
Pellikainen JM, Ropponen KM, Kataja VV, Kellokoski JK, Eskelinen MJ, Kosma VM: Expression of matrix metalloproteinase (MMP)-2 and MMP-9 in breast cancer with a special reference to activator protein-2, HER2, and prognosis. Clin Cancer Res. 2004, 10: 7621-7628. 10.1158/1078-0432.CCR-04-1061.CrossRefPubMed
17.
Murphy G: The ADAMs: signalling scissors in the tumour microenvironment. Nat Rev Cancer. 2008, 8: 929-941.CrossRefPubMed
18.
Deryugina EI, Quigley JP: Matrix metalloproteinases and tumor metastasis. Cancer Metastasis Rev. 2006, 25: 9-34. 10.1007/s10555-006-7886-9.CrossRefPubMed
19.
Liu PC, Liu X, Li Y, Covington M, Wynn R, Huber R, Hillman M, Yang G, Ellis D, Marando C: Identification of ADAM10 as a major source of HER2 ectodomain sheddase activity in HER2 overexpressing breast cancer cells. Cancer Biol Ther. 2006, 5: 657-664. 10.4161/cbt.5.6.2708.CrossRefPubMed
20.
Crawford HC, Dempsey PJ, Brown G, Adam L, Moss ML: ADAM10 as a therapeutic target for cancer and inflammation. Curr Pharm Des. 2009, 15: 2288-2299. 10.2174/138161209788682442.CrossRefPubMed
21.
Codony-Servat J, Albanell J, Lopez-Talavera JC, Arribas J, Baselga J: Cleavage of the HER2 ectodomain is a pervanadate-activable process that is inhibited by the tissue inhibitor of metalloproteases-1 in breast cancer cells. Cancer Res. 1999, 59: 1196-1201.PubMed
22.
Gouyer V, Conti M, Devos P, Zerimech F, Copin MC, Creme E, Wurtz A, Porte H, Huet G: Tissue inhibitor of metalloproteinase 1 is an independent predictor of prognosis in patients with nonsmall cell lung carcinoma who undergo resection with curative intent. Cancer. 2005, 103: 1676-1684. 10.1002/cncr.20965.CrossRefPubMed
23.
Schrohl AS, Holten-Andersen MN, Peters HA, Look MP, Meijer-van Gelder ME, Klijn JG, Brunner N, Foekens JA: Tumor tissue levels of tissue inhibitor of metalloproteinase-1 as a prognostic marker in primary breast cancer. Clin Cancer Res. 2004, 10: 2289-2298. 10.1158/1078-0432.CCR-03-0360.CrossRefPubMed
24.
Klintman M, Ornbjerg Wurtz S, Christensen IJ, Braemer Hertel P, Ferno M, Malmberg M, Mouridsen H, Cold F, Schrohl AS, Foekens JA: Association between tumor tissue TIMP-1 levels and objective response to first-line chemotherapy in metastatic breast cancer. Breast Cancer Res Treat. 2010, 121: 365-371. 10.1007/s10549-009-0483-1.CrossRefPubMed
25.
Kuvaja P, Talvensaari-Mattila A, Turpeenniemi-Hujanen T: High preoperative plasma TIMP-1 is prognostic for early relapse in primary breast carcinoma. Int J Cancer. 2008, 123: 846-851. 10.1002/ijc.23531.CrossRefPubMed
26.
Talvensaari-Mattila A, Turpeenniemi-Hujanen T: High preoperative serum TIMP-1 is a prognostic indicator for survival in breast carcinoma. Breast Cancer Res Treat. 2005, 89: 29-34. 10.1007/s10549-004-1006-8.CrossRefPubMed
27.
Lin CH, Liau JY, Lu YS, Huang CS, Lee WC, Kuo KT, Shen YC, Kuo SH, Lan C, Liu JM: Molecular subtypes of breast cancer emerging in young women in Taiwan: evidence for more than just westernization as a reason for the disease in Asia. Cancer Epidemiol Biomarkers Prev. 2009, 18: 1807-1814. 10.1158/1055-9965.EPI-09-0096.CrossRefPubMed
28.
McCracken M, Olsen M, Chen MS, Jemal A, Thun M, Cokkinides V, Deapen D, Ward E: Cancer incidence, mortality, and associated risk factors among Asian Americans of Chinese, Filipino, Vietnamese, Korean, and Japanese ethnicities. CA Cancer J Clin. 2007, 57: 190-205. 10.3322/canjclin.57.4.190.CrossRefPubMed
29.
Chen ST, Chen RA, Kuo SJ, Chien YC: Mutational screening of breast cancer susceptibility gene 1 from early onset, bi-lateral, and familial breast cancer patients in Taiwan. Breast Cancer Res Treat. 2003, 77: 133-143. 10.1023/A:1021386026051.CrossRefPubMed
30.
Hayakawa T, Yamashita K, Ohuchi E, Shinagawa A: Cell growth-promoting activity of tissue inhibitor of metalloproteinases-2 (TIMP-2). J Cell Sci. 1994, 107 (Pt 9): 2373-2379.PubMed
31.
Sugano K, Ushiama M, Fukutomi T, Tsuda H, Kitoh T, Ohkura H: Combined measurement of the c-erbB-2 protein in breast carcinoma tissues and sera is useful as a sensitive tumor marker for monitoring tumor relapse. Int J Cancer. 2000, 89: 329-336. 10.1002/1097-0215(20000720)89:4<329::AID-IJC3>3.0.CO;2-P.CrossRefPubMed
32.
Lipton A, Ali SM, Leitzel K, Demers L, Evans DB, Hamer P, Brown-Shimer S, Pierce K, Carney W: Elevated plasma tissue inhibitor of metalloproteinase-1 level predicts decreased response and survival in metastatic breast cancer. Cancer. 2007, 109: 1933-1939. 10.1002/cncr.22637.CrossRefPubMed
33.
Cook GB, Neaman IE, Goldblatt JL, Cambetas DR, Hussain M, Luftner D, Yeung KK, Chan DW, Schwartz MK, Allard WJ: Clinical utility of serum HER-2/neu testing on the Bayer Immuno 1 automated system in breast cancer. Anticancer Res. 2001, 21: 1465-1470.PubMed
34.
Kong SY, Nam BH, Lee KS, Kwon Y, Lee ES, Seong MW, Lee do H, Ro J: Predicting tissue HER2 status using serum HER2 levels in patients with metastatic breast cancer. Clin Chem. 2006, 52: 1510-1515. 10.1373/clinchem.2006.067512.CrossRefPubMed
35.
Beltran M, Colomer R: Does HER-2 status predict only a decreased response to hormone therapy in advanced breast cancer, or does it also predict the extent of metastatic disease?. J Clin Oncol. 2002, 20: 4605-10.1200/JCO.2002.99.191. author reply 4606CrossRefPubMed
36.
Fehm T, Gebauer G, Jager W: Clinical utility of serial serum c-erbB-2 determinations in the follow-up of breast cancer patients. Breast Cancer Res Treat. 2002, 75: 97-106. 10.1023/A:1019601022456.CrossRefPubMed
37.
Lipton A, Ali SM, Leitzel K, Demers L, Chinchilli V, Engle L, Harvey HA, Brady C, Nalin CM, Dugan M: Elevated serum Her-2/neu level predicts decreased response to hormone therapy in metastatic breast cancer. J Clin Oncol. 2002, 20: 1467-1472. 10.1200/JCO.20.6.1467.CrossRefPubMed
38.
Colomer R, Llombart-Cussac A, Lluch A, Barnadas A, Ojeda B, Caranana V, Fernandez Y, Garcia-Conde J, Alonso S, Montero S: Biweekly paclitaxel plus gemcitabine in advanced breast cancer: phase II trial and predictive value of HER2 extracellular domain. Ann Oncol. 2004, 15: 201-206. 10.1093/annonc/mdh048.CrossRefPubMed
39.
Ludovini V, Gori S, Colozza M, Pistola L, Rulli E, Floriani I, Pacifico E, Tofanetti FR, Sidoni A, Basurto C: Evaluation of serum HER2 extracellular domain in early breast cancer patients: correlation with clinicopathological parameters and survival. Ann Oncol. 2008, 19: 883-890. 10.1093/annonc/mdm585.CrossRefPubMed
40.
Vazquez-Martin A, Fernandez-Real JM, Oliveras-Ferraros C, Navarrete JM, Martin-Castillo B, Del Barco S, Brunet J, Menendez JA: Fatty acid synthase activity regulates HER2 extracellular domain shedding into the circulation of HER2-positive metastatic breast cancer patients. Int J Oncol. 2009, 35: 1369-1376.PubMed
41.
Amour A, Knight CG, Webster A, Slocombe PM, Stephens PE, Knauper V, Docherty AJ, Murphy G: The in vitro activity of ADAM-10 is inhibited by TIMP-1 and TIMP-3. FEBS Lett. 2000, 473: 275-279. 10.1016/S0014-5793(00)01528-3.CrossRefPubMed
42.
Bourboulia D, Stetler-Stevenson WG: Matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs): Positive and negative regulators in tumor cell adhesion. Semin Cancer Biol. 2010, 20: 161-168. 10.1016/j.semcancer.2010.05.002.PubMedCentralCrossRefPubMed
43.
Stetler-Stevenson WG: Tissue inhibitors of metalloproteinases in cell signaling: metalloproteinase-independent biological activities. Sci Signal. 2008, 1: re6-10.1126/scisignal.127re6.PubMedCentralCrossRefPubMed
44.
Akahane T, Akahane M, Shah A, Thorgeirsson UP: TIMP-1 stimulates proliferation of human aortic smooth muscle cells and Ras effector pathways. Biochem Biophys Res Commun. 2004, 324: 440-445. 10.1016/j.bbrc.2004.09.063.CrossRefPubMed
45.
Liu XW, Bernardo MM, Fridman R, Kim HR: Tissue inhibitor of metalloproteinase-1 protects human breast epithelial cells against intrinsic apoptotic cell death via the focal adhesion kinase/phosphatidylinositol 3-kinase and MAPK signaling pathway. J Biol Chem. 2003, 278: 40364-40372. 10.1074/jbc.M302999200.CrossRefPubMed
46.
Liu XW, Taube ME, Jung KK, Dong Z, Lee YJ, Roshy S, Sloane BF, Fridman R, Kim HR: Tissue inhibitor of metalloproteinase-1 protects human breast epithelial cells from extrinsic cell death: a potential oncogenic activity of tissue inhibitor of metalloproteinase-1. Cancer Res. 2005, 65: 898-906.PubMed
47.
Zhang Q, Thomas SM, Lui VW, Xi S, Siegfried JM, Fan H, Smithgall TE, Mills GB, Grandis JR: Phosphorylation of TNF-alpha converting enzyme by gastrin-releasing peptide induces amphiregulin release and EGF receptor activation. Proc Natl Acad Sci USA. 2006, 103: 6901-6906. 10.1073/pnas.0509719103.PubMedCentralCrossRefPubMed
48.
Wurtz SO, Schrohl AS, Mouridsen H, Brunner N: TIMP-1 as a tumor marker in breast cancer--an update. Acta Oncol. 2008, 47: 580-590. 10.1080/02841860802022976.CrossRefPubMed
49.
Lipton A, Leitzel K, Chaudri-Ross HA, Evans DB, Ali SM, Demers L, Hamer P, Brown-Shimer S, Pierce K, Gaur V, Carney W: Serum TIMP-1 and response to the aromatase inhibitor letrozole versus tamoxifen in metastatic breast cancer. J Clin Oncol. 2008, 26: 2653-2658. 10.1200/JCO.2007.15.4336.CrossRefPubMed
Metadata
Title
Relationships between serum HER2 ECD, TIMP-1 and clinical outcomes in Taiwanese breast cancer
Authors
Hsiu-Pei Tsai
Shin-Cheh Chen
Huei-Tzu Chien
Yi-Yin Jan
Tzu-Chieh Chao
Miin-Fu Chen
Ling-Ling Hsieh
Publication date
01-12-2012
Publisher
BioMed Central
Published in
World Journal of Surgical Oncology / Issue 1/2012
Electronic ISSN: 1477-7819
DOI
https://doi.org/10.1186/1477-7819-10-42

Other articles of this Issue 1/2012

World Journal of Surgical Oncology 1/2012 Go to the issue

Research

Pulmonary influences on early post-operative recovery in patients after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy treatment: a retrospective study

Research

Laparoscopy-assisted versus open D2 radical gastrectomy for advanced gastric cancer without serosal invasion: a case control study

Review

Meta-analysis of surgical resection and radiofrequency ablation for early hepatocellular carcinoma

Research

Laparoscopic versus open colectomy for colon cancer in an older population: a cohort study

Case report

Conjunctival lymphoma arising from reactive lymphoid hyperplasia

Case report

Presentation of two patients with malignant granulosa cell tumors, with a review of the literature